Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAmylyx Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.48 | -$0.48 | -$0.48 |
| Q2 2025 | 3 | -$0.45 | -$0.42 | -$0.44 |
| Q3 2025 | 1 | -$0.46 | -$0.46 | -$0.46 |
| Q4 2025 | 1 | -$0.47 | -$0.47 | -$0.47 |
Amylyx Pharmaceuticals, Inc. Earnings Date And Information
Amylyx Pharmaceuticals, Inc. last posted its earnings results on Thursday, May 8th, 2025. The company reported $-0.42 earnings per share for the quarter, topping analysts' consensus estimates of $-0.45 by $0.03. The company had revenue of 0 for the quarter and had revenue of 87.37 M for the year. Amylyx Pharmaceuticals, Inc. has generated $-4 earnings per share over the last year ($-4.43 diluted earnings per share) and currently has a price-to-earnings ratio of -2.1. Amylyx Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based on prior year's report dates.
Amylyx Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/08/2025 | Q1 2025 | -$0.45 | -$0.42 | 0.03 | $58.15 M | $0 |
| 03/04/2025 | Q4 2024 | -$0.49 | -$0.55 | -0.06 | $32.59 M | $-665,000 |
| 11/07/2024 | Q3 2024 | -$0.47 | -$1.07 | -0.6 | $31.57 M | $416.00 K |
| 08/08/2024 | Q2 2024 | -$0.38 | -$1.07 | -0.69 | $10.66 M | $-1,023,000 |
| 05/09/2024 | Q1 2024 | $0.24 | -$1.75 | -1.99 | $98.35 M | $88.64 M |
| 02/22/2024 | Q4 2023 | $0.23 | $0.07 | -0.16 | $106.96 M | $108.45 M |
| 11/09/2023 | Q3 2023 | $0.44 | $0.31 | -0.13 | $113.66 M | $102.69 M |
| 08/10/2023 | Q2 2023 | $0.10 | $0.33 | 0.23 | $92.21 M | $98.22 M |
| 05/11/2023 | Q1 2023 | -$0.24 | $0.02 | 0.26 | $58.99 M | $71.43 M |
| 03/13/2023 | Q4 2022 | -$0.77 | -$0.65 | 0.12 | $4.72 M | $21.89 M |
| 11/10/2022 | Q3 2022 | -$0.97 | -$0.92 | 0.05 | $83.33 K | $345.00 K |
| 08/11/2022 | Q2 2022 | -$0.92 | -$0.93 | -0.01 | $125.00 K | $0 |
| 05/12/2022 | Q1 2022 | -$0.75 | -$0.93 | -0.18 | $83.33 K | $0 |
| 03/31/2022 | Q4 2021 | N/A | -$0.51 | N/A | $338.33 K | $0 |
| 09/30/2021 | Q3 2021 | N/A | -$0.42 | N/A | N/A | $285.00 K |
| 06/30/2021 | Q2 2021 | N/A | -$0.48 | N/A | N/A | $0 |
| 03/31/2021 | Q1 2021 | N/A | -$0.32 | N/A | N/A | $0 |
| 12/31/2020 | Q4 2020 | N/A | -$0.19 | N/A | N/A | $350.00 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Amylyx Pharmaceuticals, Inc. Earnings: FAQ's
Amylyx Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based offlast year's report dates.
In the previous quarter, Amylyx Pharmaceuticals, Inc. (:AMLX) reported $-0.42 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.45 by $0.03.
The conference call for Amylyx Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Amylyx Pharmaceuticals, Inc.'s latest earnings report can be read online.
Amylyx Pharmaceuticals, Inc. (:AMLX) has a recorded annual revenue of $87.37 M.
Amylyx Pharmaceuticals, Inc. (:AMLX) has a recorded net income of $-301,743,000.Amylyx Pharmaceuticals, Inc. has generated $-4.43 earnings per share over the last four quarters.
Amylyx Pharmaceuticals, Inc. (:AMLX) has a price-to-earnings ratio of -2.1 and price/earnings-to-growth ratio is -0.07.